ISRIB as a promising therapeutic for Fragile X syndrome
ISRIB as a promising therapeutic for Fragile X syndrome
批准号:
10297829
负责人:
ROCHELLE LYNN COULSON
金额:
$6.86万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-17 至 2023-07-16
关键词:
AMPA ReceptorsAddressAffectAnxietyArray tomographyAwardBehavioralBehavioral AssayBiological AssayChildCognitionCognitiveCognitive deficitsDataDendritic SpinesDevelopmentDevelopment PlansDiseaseEducational workshopEnrollmentEnvironmentEtiologyFMR1FoundationsFragile X SyndromeGeneticGenetic TranslationGoalsGrantHomeostasisHyperactivityImageImaging TechniquesImpairmentIndividualInheritedIntellectual functioning disabilityKnock-outKnockout MiceKnowledgeLearningLong-Term DepressionManuscriptsMeasuresMediatingMembraneMemory impairmentMolecularMolecular BiologyMusNeurodevelopmental DisorderNeuronsOutcomeOutcomes ResearchPathologyPathway interactionsPatientsPharmaceutical PreparationsPhenotypeProgram DevelopmentProtein BiosynthesisProtein DeficiencyQuality of lifeRegulationResearchResearch ActivityRoleSocial BehaviorSpeech DelayStructureSurfaceSynapsesSynaptic MembranesSynaptic plasticitySystemTechniquesTestingTherapeuticTherapeutic InterventionTrainingTraining ActivityTraumatic Brain InjuryVertebral columnVisualizationWestern BlottingWorkWritingautism spectrum disorderautistic behaviourbehavior testbehavioral phenotypingbiological adaptation to stresscareercareer developmentcognitive performancecognitive testingdefined contributionimprovedin vivoinhibitor/antagonistlong term memorymodel developmentmolecular imagingmorris water mazemouse modelnew therapeutic targetnovelnovel therapeutic interventionnovel therapeuticsobject recognitionprogramsresponserestorationsmall moleculesocialsocial deficitssymposiumsymptom treatmenttargeted treatmenttreatment strategytwo photon microscopytwo-photon
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Fragile X syndrome (FXS) is a neurodevelopmental disorder characterized by cognitive and behavioral
difficulties including intellectual disability, anxiety, hyperactivity, and many other autistic behaviors. FXS is the
leading genetic cause of intellectual disability, affecting millions of children worldwide, however, there is currently
no cure. FXS is caused by the absence of the Fragile X Mental Retardation Protein (FMRP). This FMRP
deficiency activates the integrated stress response (ISR), promoting the internalization of AMPA receptors,
concomitant with deficits in dendritic spine maturation and turnover. These synaptic deficits likely underlie the
cognitive deficits observed in FXS. New therapeutic strategies have immense potential for the improvement of
FXS patient quality of life, however there are currently no therapies targetting the ISR. The overall objective of
this proposal is to determine the efficacy of ISR modulation by the novel drug ISRIB (ISR inhibitor) in normalizing
the synaptic and cognitive deficits observed in FXS. Our central hypothesis is that blocking the ISR with ISRIB
will stabilize spine maturation and turnover, alleviating the behavioral and cognitive deficits observed in FXS.
Utilizing an Fmr1 knockout (KO) mouse model of FXS, we will address this hypothesis in the following specific
aims: 1) Determine the effect of ISRIB treatment on synaptic phenotypes in Fmr1 KO mice and 2) Determine the
effect of ISRIB treatment on cognitive and social deficits in Fmr1 KO mice. We will address these aims using a
combination of molecular, imaging, and behavioral techniques. We will determine the effect of ISRIB treatment
on spine maturation by measuring the abundance of post-synaptic membrane-bound AMPA receptors and spine
dynamics by measuring the rate of formation and elimination. The effect of ISRIB on behavioral phenotyes will
be assayed by a battery of social and cognitive tests. The outcomes of this research will define the role of the
ISR in the etiology of FXS and has the potential to provide a foundation for the development of new strategies
for therapeutic intervention in FXS.
I have developed a detailed, tailored development plan for my training during this award period including
technical, scientific, and professional training activities. I will build on my strong foundation in molecular biology
as well as gain technical training in array tomography, two-photon microscopy, and mouse behavioral analysis.
For scientific training, I will enroll in both formal courses as well as participate in seminars at Stanford.
Professionally, I will enhance my career development through workshops, conference participation, and grant
and manuscript writing programs. The training environment in Dr. Mourrain’s lab and at Stanford is exceptional.
In addition to my research activities, in which I will gain new technical and scientific expertise, I will participate in
a variety of development programs offered at Stanford including workshops in building a successful path to an
independent academic career. Dr. Mourrain is committed to my comprehensive training and together we have
developed a plan that will enable me to gain increasing independence throughout the course of my training.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ISRIB as a promising therapeutic for Fragile X syndrome
-
批准号:10442548
-
项目类别:
-
资助金额:$7.17万
-
财政年份:2020
-
负责人:ROCHELLE LYNN COULSON
-
依托单位:
海外基金